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Highlights:
 Since 2010, initiations of VPA have decreased among girls aged 0 to 14 years.
 Initiations of LTG and LEV increased among girls over the study period. 
 In 2016, GPs were still initiating VPA among girls aged 11-14 years.
 GPs remain the primary healthcare professionals for epileptic patients.
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Abbreviations: 
AED Antiepileptic drugs
ANSM Agence Nationale de Sécurité des Médicaments des produits de santé (French 
agency for the safety of medicines and health products)
ATC Anatomical Therapeutic Chemical
CCAM Classification Commune des Actes Médicaux
CIP Code identification produit (national registration code)
CMUc Couverture médicale universelle complémentaire (Complementary Universal 
Health Insurance)
DCIR Données de Consommation Inter-Régimes (Health reimbursement database)
DP Diagnostic principal (main diagnose)
DR Diagnostic relié (related diagnose)
DAS Diagnostic associé significatif (significant related diagnose)
EEG Electroencephalogram
EMA European Medicines Agency
GP General practitioner
ICD International Classification of Diseases
LEV Levetiracetam
LTI Long-Term Illness
LTG Lamotrigine
PMSI Programme de Médicalisation du système d’information (French hospital 
discharge database)
PY Person-Year
SNIIRAM Système National d’Information Inter-Régimes de l’Assurance Maladie (French 
National Health Insurance Database)
VPA Sodium valproate
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1) Introduction
Epilepsy is one of the commonest serious chronic neurological disorders. Worldwide there are 
at least 65 million people living with epilepsy. The incidence of epilepsy in the infantile 
period is high, with an estimation of about 70 per 100,000 inhabitants in European countries. 
[1] 
The management of epilepsy among children is different from that among adults because of a 
broader spectrum of syndromes in children and because evidence on the effectiveness of 
antiepileptic drugs (AEDs) is not always established. [2–4] A therapeutic choice must still be 
made even if a precise diagnosis is not straightforward at the onset of epilepsy.
In the 2000s, new AEDs arrived on the drug market and changed practices in the treatment of 
epilepsy for both children and adults. [5,6] The changes could also be related to an awareness 
of the risks associated with in utero exposure to earlier antiepileptic drugs, such as sodium 
valproate (VPA), which has been integrated into clinicians’ practices, especially neurologists, 
as demonstrated in Europe and across the Atlantic. [7–9] In 2014, as recommended by the 
European Medicines Agency (EMA), the French Agency for the safety of medicines and 
health products (ANSM) initiated a communication strategy with a "Dear Doctor” letter [10] 
to remind healthcare professionals of the teratogenic effects of VPA (major congenital 
malformations [11], neuro-developmental delays [12], autism spectrum disorders [13,14]). A 
few months later, in May 2015, French clinicians were also informed that the conditions for 
prescription and issue of VPA and its derivatives would be reinforced. [15] Since the 1st of 
January 2016, VPA and its derivatives should, whenever it is possible, not be prescribed to 
women of childbearing age, except in case of intolerance or ineffectiveness of alternatives. 
Nonetheless, the unchallenged efficacy of VPA, with its broad spectrum of activity, makes it a 
drug of choice for the first-line treatment of epilepsy.[16] More recently in Europe, likewise, 
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VPA has been contraindicated for women of reproductive potential, except in case of 
intolerance or ineffectiveness of alternatives.
We aimed to evaluate trends in AED prescriptions, especially in the period 2015-2016, to 
tailor a communication strategy, focusing on young epileptic girls, for whom VPA should not 
be chosen as the first-line treatment.
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1)  Methods
We conducted a nationwide study using the French National Health Insurance Database 
(SNIIRAM), over 7 years (2010-2016), to describe the trends in VPA prescription among 
epileptic girls 0 to 14 years of age, particularly as first-line treatment, and we compared this 
with prescribing trends for boys aged 0 to 14 years. 
Source
SNIIRAM anonymously and comprehensively links a health reimbursement database (DCIR) 
to the French hospital discharge database (PMSI). The DCIR contains i) demographic data 
such as date of birth, gender and information on complementary insurance systems or the 
presence of CMUc (Couverture médicale universelle complémentaire) (Complementary 
Universal Health Insurance), an insurance cover for low‐income status individuals ii) 
medication, recorded as dispensed packs, including a single national registration code (CIP), 
and Anatomical Therapeutic Chemical (ATC) code is also provided with the date of 
prescription, the profession of the prescriber and date of issue iii) the presence of long-term 
illness (LTI) status and date of first registration of chronic illness status, which gives 
registered patients full coverage for all medical expenses related to the illness. PMSI covers 
all overnight or day hospitalizations in the public and private sectors, and includes short-term 
stays in medical, surgical or obstetric facilities. It collects information on the patients and 
their diagnoses (primary diagnoses (DP—diagnostic principal /DR—diagnostic relié) (main 
and related diagnoses)) and comorbidities or complications (DAS—Diagnostic associé 
significatif) (significant related diagnoses) using ICD10 codes (International Classification of 
Diseases, 10th revision), surgical/interventional procedures (CCAM–Classification Commune 
des Actes Médicaux) and prescription of particularly expensive drugs. 
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The SNIIRAM database was developed to ensure the reimbursement of individual medical 
claims but was not intended to serve medical research. It does not comprise any clinical 
information concerning results related to consultations, prescriptions or examinations. Using 
it to follow individual patients over time and across different data sets can therefore be 
challenging.
It has previously been used to describe prescription trends with respect to recommendations 
[17] in the context of epilepsy management [18] and VPA exposure [19].
Patient selection
All patients aged 0 to 14 years with at least one issue of antiepileptic drug (AED) recorded 
between 2010 and 2016 were selected. An AED was defined as a drug licensed for the 
treatment of epilepsy in France, i.e. drugs listed under the ATC code N03A, plus two 
benzodiazepines, diazepam (N05BA01) and clobazam (N05BA09). As diazepam is mainly 
authorized for febrile convulsions, patients who were prescribed diazepam only were 
excluded. Patients, who were prescribed sodium divalproex (N03AG01) or valpromide 
(N03AG02) were also excluded because these medications are mostly indicated in psychiatric 
setting. 
Data collection
For descriptive purposes different patient characteristics were collected: date of birth to 
determine the age at the beginning of the study (January 1st, 2010), gender, LTI status, CMUc 
status, which provides information on patient socio-economic level. Prescription 
characteristics were obviously studied: date of prescription, date of issue, drug issued, number 
of boxes and also information on the prescriber, as working in a healthcare facility or in the 
community. 
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Statistical analysis
For each patient matching the selection criteria and for each prescription we determined 
whether it was a prevalent or an incident use (first delivery after birth or after one year 
without AED issue). A one-year history was necessary to obtain this information and this is 
the reason why we retrospectively collected data up to 2009. We also determined which 
AEDs were prescribed (grouping them by ATC7 Code). The number of different ATC7 codes 
prescribed defined the polytherapy criterion. 
For each year, we first calculated the percentage of VPA and that of each ATC7 code other 
than VPA among incident uses, and plotted these proportions by gender and age category. We 
use the following age categories: 0-2 years, 3-6 years, 7-10 years and 11-14 years. For 
purposes of comparison, we calculated the relative reduction in prescriptions between the 
percentage of VPA prescribed in 2010-2014 and the one in 2016. We intentionally excluded 
the year 2015, during which time the EMA and ANSM promoted a huge campaign to avoid 
the use of VPA among women of childbearing age. The impact of the 2015 risk minimization 
measure was likely to be more obvious in 2016, the year we chose for comparison.
We then calculated the incidence rate of VPA prescription among prevalent uses of any other 
AEDs and plotted them by gender and age category: the number of VPA initiations was 
divided by the number of person-years (PY) with a prevalent use of another AED. The types 
of AED before VPA initiation were described. 
Finally we calculated the incidence rate for VPA discontinuations among prevalent users of 
VPA and the proportion for each ATC7 code among AED prescriptions after VPA 
discontinuation. VPA discontinuation was defined by the last VPA delivery date followed by 
at least one year without VPA issue, assuming one year of follow-up was available.
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Statistical analyses were performed using SAS 9.4 (SAS INSTITUTE, North Carolina, USA) 
via SAS Enterprise Guide®.
Regulatory approval
The study was granted regulatory approval as part of a larger program on VPA exposure 
(CNIL 03/11/2016). The study was conducted with direct access to the SNIIRAM database 
under ANSM agreement.
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2) Results
General characteristics of the study population
In the SNIIRAM database, 113,362 children fulfilled the selection criteria, 61,259 boys and 
52,103 girls. Almost all patient characteristics were similar between boys and girls (Table 1). 
The number of incident uses over the study period (seven years) was 93,557: 42,493 among 
girls and 50,064 among boys. The median age at the beginning of the study was five years. 
The most frequently prescribed antiepileptic drugs were, in decreasing order: sodium 
valproate, largely predominant, followed by diazepam, lamotrigine (LTG), levetiracetam 
(LEV), clobazam and clonazepam. Most of the drugs were prescribed in monotherapy. 
Prescribing trends for sodium valproate
Figure 1 shows the trends in VPA initiations over the study period by gender and age 
category. Focusing on children aged 0-10 years and incident uses only in 2010, the proportion 
of VPA prescriptions ranged between 40 and 50%, without a clear gap between boys (nearly 
30%) and girls (20%). Globally, the proportion remained quite stable until 2014 and then 
decreased. In 2016, the proportion of VPA still accounted for 11% of AED initiations among 
girls aged 11-14 years. 
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Figure 1. Trends in sodium valproate initiations over the study period by gender and age 
category. (2-column fitting image)
Between 2010 and 2016, the proportions of prescriptions for LEV, LTG, ethosuximide, 
gabapentin in incident use increased among girls aged 0-14 years (Figure 2).
Table 2 reports the proportion of VPA among AED initiations according to prescriber 
category. In 2010, initiation of VPA among girls by specialists (including hospital practitioner 
and neurologist or pediatrician working in community) was relatively frequent (over 40%). 
This frequency was lower in 2016 for neurologists (-24.5% between 2010 and 2016), hospital 
practitioners (-20.6%) and pediatricians (-15.6%). In contrast, the frequency of VPA use 
among AED initiations by General Practitioners (GPs) was relatively stable over the period, at 
around 20-25%.
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Figure 2. Trends in antiepileptic treatment initiations over the study period among girls aged 
0-14 years. (1-column fitting image)
Figure 3 shows trends in initiating VPA (add-on or switch) among prevalent users of any 
AED other than VPA over the study period by gender and age category. The number of PY 
treated with an AED other than VPA was around 5000 per year over the study period. In this 
population, the incidence rate for VPA prescription decreased from 18.3 in 2010 to 9.7 per 
100 PY in 2016 for girls (47% relative reduction) versus 20.3 to 16.1 per 1000 PY for boys 
(relative reduction of 21%). These relative reductions were homogeneous across the different 
age groups. 
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It can be noted that the incidence rate for VPA prescription among teenage girls (11-14 years 
of age) and young girls (7-10 years of age) was relatively low over the study period (less than 
10 for 100 PY). The most frequently prescribed AEDs just before VPA initiation were 
benzodiazepines, lamotrigine and vigabatrine, mostly in monotherapy (91% in 2010; 89% in 
2015).
Figure 3. Trends in sodium valproate initiations (add-on or switch) among children already 
treated with another antiepileptic drug over the study period, by gender and age category. (2-
column fitting image)
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Discontinuation of VPA was defined as an issue of VPA that was not followed later in the 
year by another issue of VPA, assuming one year of follow-up was available. Discontinuation 
of VPA was quite high (around 35 per 100 child-years) but quite stable over the study period 
and similar in girls and in boys. It was higher among young children (0-6 years old) than 
among older children (7-14 years old) (40 to 60 per 100 PY versus 30 per 100 PY). 
In around 70% of cases, VPA discontinuation was not followed by another AED. Before 
withdrawal of sodium valproate treatment, the antiepileptic treatment duration was for the 
majority 1 year or more (60%), while in 18% of cases it was less than 1 month (only 1 issue). 
It was different among children aged 0-2 years, for whom only 1 month of antiepileptic 
treatment before VPA withdrawal was observed in 30% of cases. 
The remaining 30% “switched” from VPA to another AED, mostly in monotherapy. 
Lamotrigine and levetiracetam were the most frequently prescribed AEDs.
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Discussion
Our study evaluating the trends in sodium valproate (VPA) prescription among children 
highlighted a number of points. 
Firstly, the proportion of VPA prescriptions among incident uses of antiepileptic drugs 
decreased in both genders over the study period, but more so among girls, especially in 
teenage girls. Over the 1993 to 2006 period, the prevalence of VPA per 1000 prescriptions 
among females (12-18 years old) significantly decreased from 0.94 (95% CI 0.80 to 1.09) to 
0.63 (95% CI 0.55 to 0.72). [7]. Over the 2000 to 2010 period, girls were prescribed sodium 
valproate significantly less often as a first-line AED (74% versus 46%). [20] Our study 
enables these observations to be updated and it points to a substantial decrease in VPA use 
among teenage girls, possibly as a result of new information released in the media on its 
teratogenic effects. [10] 
Secondly, the alternatives to VPA, for which frequencies increased during the study period, 
were mainly levetiracetam, then lamotrigine, followed by ethosuximide and gabapentin. 
Increases were always more pronounced for girls than for boys. Changes in the choice of the 
first AED for a new onset of epilepsy are similar to those observed in previous years in other 
European countries. [7,9,20] During the 2000s, it was established that the use of first-
generation AEDs (VPA, carbamazepine, phenytoin, phenobarbital) decreased over time, at 
least in developed countries, concomitantly with the arrival of new AEDs on the market. 
[5,9,21,22] More recently, a trend towards more LEV and LTG prescriptions could also be 
explained by prescribers’ knowledge of the significantly lower rates of major congenital 
malformations for these drugs. [11] 
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Thirdly, the proportion of VPA initiations among girls already under treatment greatly 
decreased for specialists but remained stable over the study period for GPs. The proportions 
of AED prescriptions by three different prescriber categories (GPs, specialists, psychiatrists) 
were studied by Hollingworth & al. in Australia over a 5-year period (2002-2007). They 
observed an increase in prescribing of new AEDs, such as levetiracetam, topiramate and 
lamotrigine, by GPs. Also, the proportion of prescriptions by GPs was the highest for 
phenytoin, followed by sodium valproate. [23] Prescriber data in this study indicated a shift 
from specialist to GP prescribing. Neurologists commonly initiate AED prescription for 
epilepsy and the subsequent prescribing is usually taken on by GPs. This pattern should be 
applied in France according to the latest recommendations. Nevertheless, VPA accounted for 
20% of AEDs initiated by a GP. In the clinical context of epilepsy, primary care should lead 
to an initiation of antiepileptic treatment to limit possible seizures and should not have to be 
delayed until the final therapeutic choice made by a specialist. Continuing prescription of 
VPA as first-line treatment by GPs could reflect difficulties in healthcare trajectories for the 
French epileptic population, with difficult access to specialized care (EEG, neurologist, 
tertiary care hospitals), compelling GPs to ensure the care of first seizures with VPA, on the 
grounds that this AED has a broad spectrum of activity. 
Finally, discontinuation of VPA was stable over the study period, among girls but also among 
boys, and did not seem to be influenced by the recommendations. In 70% of cases, the 
withdrawal of VPA was not followed by another AED, and this was all the more true among 
children aged 0-2 years. The exact reasons why treatments were discontinued is not known, 
but some situations can justify it. For instance, treatment with VPA can be discontinued after 
a diagnosis of recovery. VPA is the drug of choice for many epileptic syndromes, and widely 
prescribed by GPs. After specialist consultation or access to electroencephalogram (EEG), a 
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diagnosis other than epilepsy can be made. An antiepileptic treatment can also be prescribed 
on a temporary basis, for example in case of accidental seizure after meningitis, head trauma, 
or febrile seizures. In these cases, the treatment duration is short (a few months) and pursuit of 
antiepileptic treatment is not expected. Among older children, discontinuation of the 
antiepileptic treatment can occur in certain types of syndrome (childhood absence epilepsy, 
benign rolandic epilepsy) after a seizure-free period, or to limit the neurocognitive impact of 
AEDs. Prolonged discontinuations do not systematically lead to seizure recurrence and are 
possible for some patients. [30, 31]
Compared to previous studies, our investigation, by using a large population database over a 
recent period of time, is the first one that evaluates latest trends in prescribing valproate 
focusing on children. 
A first limitation is the definition of incident use, which could include a re-instatement of 
treatment, as it was based on a one-year AED-free period only. However, recommendations 
on VPA use encompass AED initiation as well as resumption of treatment. A second 
limitation is the fact that the SNIIRAM database does not enable the pathological context of 
prescriptions to be identified because no clinical data is available except for the hospital 
discharge diagnoses.. Nevertheless, we believe that AEDs are primarily prescribed in children 
for anticonvulsant purposes and, more importantly, our objective was to observe a decrease in 
valproate prescribing trends regardless of indication. Finally, patients in long-term facilities 
were not included in this study because AED issues for these patients were not available in 
the database. These patients often have pharmaco-resistant epilepsy, or at least epilepsy that is 
hard to stabilize with different AED prescription strategies. [23, 24]
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Conclusion
To the best of our knowledge, this is the first study describing VPA and alternative 
prescription patterns in a large pediatric population over a long period of time taking into 
account the new French recommendations concerning VPA use. This large-scale study 
describes changes in paediatric prescription patterns following the implementation of a 
national information campaign on the appropriate use of VPA.
The observed trend was as expected, with a decrease in VPA initiations, especially after 2015, 
among children whether or not already treated with an AED. This decrease was observed in 
both genders, more pronounced for girls, and sharper in 2016. The proportion of VPA 
prescriptions among the different AED prescriptions decreased between 2010 and 2016 in 
favor of LTG and LEV, often used as monotherapy. Whatever the nature of the prescription 
(initiation or not), they came mainly from hospital prescribers (specialists) and from 
neurologists or pediatricians.
All prescribers reduced VPA prescriptions between 2010 and 2016, especially the 
neurologists. VPA initiation remained stable among GPs. In 2016, the Prescription and Drug 
Supply Conditions changed for VPA in France: it is now mandatory for it to be initiated by a 
specialist. Furthermore, the European Medicines Agency recently changed the 
recommendations for VPA use: it should not be prescribed to women of childbearing potential 
except if there is no other treatment option, and provided the woman is on adequate 
contraception. Further evaluations in 2016, 2017 and 2018 could be valuable.
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Table 1: Characteristics of the study population.
 Girls (N=52103) Boys (N=61259)
Age*, median (quartiles) 5 (1-9) 5 (1-9)
LTI = Epilepsy, n (%) 11541 (22,2) 13470 (22,0)
CMUC, n (%) 15719 (30,2) 19780 (32,3)
Hospitalization for epileptic seizure†, n (%) 14449 (27,7) 17497 (28,6)
Initiation of an antiepileptic treatment†, n (%) 42493 (81,6) 50064 (81,7)
Annual density of prescription of AED‡, median (quartiles) 11,9 (8,8 - 12,2) 11,7 (8,7-12,2)
Number of ATC classes experimented by child†, n (%)   
1 class    27126 (52,1) 31700 (51,7)
2 classes 14508 (27,8) 17640 (28,8)
>=3 classes 10469 (20,1) 11919 (19,5)
Taking AED treatment**, n (%)
Sodium valproate 27508 (52,8) 35873 (58,6)
Diazepam 16227 (31,1) 20529 (33,5)
Lamotrigine 8813 (16,9) 7493 (12,2)
Levetiracetam 8406 (16,1) 9043 (14,8)
Clobazam 7988 (15,3) 9229 (15,1)
Clonazepam 6824 (13,1) 8163 (13,3)
Carbamazepine 4161 (8,0) 5615 (9,2)
Topiramate 3416 (6,6) 3605 (5,9)
Ethosuximide 2711 (5,2) 2471 (4,0)
Oxcarbazepine 2603 (5,0) 3242 (5,3)
Phenytoine 209 (0,4) 261 (0,4)
Majority type of AED prescriptions†, n (%)   
>50% of prescriptions in monotherapy without VPA 25539 (49,0) 26525 (43,3)
>50% of prescriptions in monotherapy with VPA 19019 (36,5) 25743 (42,0)
>50% of prescriptions in polytherapy without VPA 2030 (3,9) 2219 (3,6)
>50% of prescriptions in polytherapy with VPA 2877 (5,5) 3611 (5,9)
No majority type of AED prescriptions 2638 (5,1) 3161 (5,2)
* Parameter calculated at the beginning of the study period, i.e. the first of January 2010.
† Parameter calculated over the study period (From 2010 until 2016).
‡ Parameter calculated over the period of prescription (from the first prescription until the last prescription identified over the study period 
before the age of 14.
** At least one supply of the AED before the age de 14 and over the study period.
LTI denotes long-term illness status which gives entitlement to full health care reimbursement, CMUC Complementary Universal Health 
Insurance status, which provides information on the patients’ socio-economic level, AED antiepileptic drug, ATC Anatomical Therapeutic 
Chemical.
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Table 2: Proportion of VPA among AED treatment initiations, by prescriber category.
Sodium valproate 2010 2011 2012 2013 2014 2015 2016*
N 4243 4330 4325 4320 4195 4081 2255
n 1807 1740 1703 1721 1552 1343 495
Hospital 
practitioner**
% 42.59 40.18 39.38 39.84 37.00 32.91 21.95
N 1901 1684 1378 1243 1223 1184 645
n 438 406 426 372 360 281 130
General 
practitioner
% 23.04 24.11 30.91 29.93 29.44 23.73 20.16
N 288 275 275 237 246 233 130
n 138 122 130 116 107 110 42
Pediatrician
% 47.92 44.36 47.27 48.95 43.50 47.21 32.31
N 428 348 338 338 339 336 172
N 177 145 131 132 116 80 29
Girls
0-14 
years
Neurologist
% 41.36 41.67 38.76 39.05 34.22 23.81 16.86
N 5250 5357 5199 5054 5071 4913 2853
n 2348 2323 2199 2145 2119 1946 1082
Hospital 
practitioner**
% 44.72 43.36 42.30 42.44 41.79 39.61 37.92
N 2083 1979 1590 1437 1401 1273 653
n 523 546 602 469 421 351 153
General 
practitioner
% 25.11 27.59 37.86 32.64 30.05 27.57 23.43
N 299 295 327 307 319 289 149
n 142 129 130 152 164 131 66
Pediatrician
% 47.49 43.73 39.76 49.51 51.41 45.33 44.30
N 401 357 311 357 310 308 167
n 177 171 159 162 146 126 58
Boys
0-14 
years
Neurologist
% 44.14 47.90 51.13 45.38 47.10 40.91 34.73
N = number of prescriptions initiated by the prescriber category
n = number of prescriptions of VPA among the previous N
*up to 31/07/2016
**physician working in a hospital, considered as a specialist
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Highlights:
 Since 2010, initiations of VPA have decreased among girls aged 0 to 14 years.
 Initiations of LTG and LEV increased among girls over the study period. 
 In 2016, GPs were still initiating VPA among girls aged 11-14 years.
 GPs remain the primary healthcare professionals for epileptic patients.
 VPA is still the drug of choice for first-line treatment.
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Abstract 
Purpose
After a huge campaign of information on the teratogenic risk of sodium valproate (VPA) 
having taken place in France we aimed to evaluate the trend of its prescriptions in young 
epileptic girls.
Method
Using the French National Health Insurance Database we searched for patients aged 0 to 14 
years being supplied an antiepileptic drug (AED) between 2010 and 2016. 
Results
113,362 children received at least one AED, 61,259 boys and 52,103 girls. Compared to 
2010-2014 years, VPA was less prescribed in 2016 as first AED (29% vs 37.3% respectively). 
The difference between the two periods was greater for girls (-41%) than for boys (-12%).
Conclusion
The changing trend of VPA as first AED prescribed, particularly in girls, reflects published 
evidence in terms of safety. 
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Highlights:
 Since 2010, initiations of VPA have decreased among girls aged 0 to 14 years.
 Initiations of LTG and LEV increased among girls over the study period. 
 In 2016, GPs were still initiating VPA among girls aged 11-14 years.
 GPs remain the primary healthcare professionals for epileptic patients.
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Abbreviations: 
AED Antiepileptic drugs
ANSM Agence Nationale de Sécurité des Médicaments des produits de santé (French 
agency for the safety of medicines and health products)
ATC Anatomical Therapeutic Chemical
CCAM Classification Commune des Actes Médicaux
CIP Code identification produit (national registration code)
CMUc Couverture médicale universelle complémentaire (Complementary Universal 
Health Insurance)
DCIR Données de Consommation Inter-Régimes (Health reimbursement database)
DP Diagnostic principal (main diagnose)
DR Diagnostic relié (related diagnose)
DAS Diagnostic associé significatif (significant related diagnose)
EEG Electroencephalogram
EMA European Medicines Agency
GP General practitioner
ICD International Classification of Diseases
LEV Levetiracetam
LTI Long-Term Illness
LTG Lamotrigine
PMSI Programme de Médicalisation du système d’information (French hospital 
discharge database)
PY Person-Year
SNIIRAM Système National d’Information Inter-Régimes de l’Assurance Maladie (French 
National Health Insurance Database)
VPA Sodium valproate
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1) Introduction
Epilepsy is one of the commonest serious chronic neurological disorders. Worldwide there are 
at least 65 million people living with epilepsy. The incidence of epilepsy in the infantile 
period is high, with an estimation of about 70 per 100,000 inhabitants in European countries. 
[1] 
The management of epilepsy among children is different from that among adults because of a 
broader spectrum of syndromes in children and because evidence on the effectiveness of 
antiepileptic drugs (AEDs) is not always established. [2–4] A therapeutic choice must still be 
made even if a precise diagnosis is not straightforward at the onset of epilepsy.
In the 2000s, new AEDs arrived on the drug market and changed practices in the treatment of 
epilepsy for both children and adults. [5,6] The changes could also be related to an awareness 
of the risks associated with in utero exposure to earlier antiepileptic drugs, such as sodium 
valproate (VPA), which has been integrated into clinicians’ practices, especially neurologists, 
as demonstrated in Europe and across the Atlantic. [7–9] In 2014, as recommended by the 
European Medicines Agency (EMA), the French Agency for the safety of medicines and 
health products (ANSM) initiated a communication strategy with a "Dear Doctor” letter [10] 
to remind healthcare professionals of the teratogenic effects of VPA (major congenital 
malformations [11], neuro-developmental delays [12], autism spectrum disorders [13,14]). A 
few months later, in May 2015, French clinicians were also informed that the conditions for 
prescription and issue of VPA and its derivatives would be reinforced. [15] Since the 1st of 
January 2016, VPA and its derivatives should, whenever it is possible, not be prescribed to 
women of childbearing age, except in case of intolerance or ineffectiveness of alternatives. 
Nonetheless, the unchallenged efficacy of VPA, with its broad spectrum of activity, makes it a 
drug of choice for the first-line treatment of epilepsy.[16] More recently in Europe, likewise, 
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VPA has been contraindicated for women of reproductive potential, except in case of 
intolerance or ineffectiveness of alternatives.
We aimed to evaluate trends in AED prescriptions, especially in the period 2015-2016, to 
tailor a communication strategy, focusing on young epileptic girls, for whom VPA should not 
be chosen as the first-line treatment.
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1)  Methods
We conducted a nationwide study using the French National Health Insurance Database 
(SNIIRAM), over 7 years (2010-2016), to describe the trends in VPA prescription among 
epileptic girls 0 to 14 years of age, particularly as first-line treatment, and we compared this 
with prescribing trends for boys aged 0 to 14 years. 
Source
SNIIRAM anonymously and comprehensively links a health reimbursement database (DCIR) 
to the French hospital discharge database (PMSI). The DCIR contains i) demographic data 
such as date of birth, gender and information on complementary insurance systems or the 
presence of CMUc (Couverture médicale universelle complémentaire) (Complementary 
Universal Health Insurance), an insurance cover for low‐income status individuals ii) 
medication, recorded as dispensed packs, including a single national registration code (CIP), 
and Anatomical Therapeutic Chemical (ATC) code is also provided with the date of 
prescription, the profession of the prescriber and date of issue iii) the presence of long-term 
illness (LTI) status and date of first registration of chronic illness status, which gives 
registered patients full coverage for all medical expenses related to the illness. PMSI covers 
all overnight or day hospitalizations in the public and private sectors, and includes short-term 
stays in medical, surgical or obstetric facilities. It collects information on the patients and 
their diagnoses (primary diagnoses (DP—diagnostic principal /DR—diagnostic relié) (main 
and related diagnoses)) and comorbidities or complications (DAS—Diagnostic associé 
significatif) (significant related diagnoses) using ICD10 codes (International Classification of 
Diseases, 10th revision), surgical/interventional procedures (CCAM–Classification Commune 
des Actes Médicaux) and prescription of particularly expensive drugs. 
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The SNIIRAM database was developed to ensure the reimbursement of individual medical 
claims but was not intended to serve medical research. It does not comprise any clinical 
information concerning results related to consultations, prescriptions or examinations. Using 
it to follow individual patients over time and across different data sets can therefore be 
challenging.
It has previously been used to describe prescription trends with respect to recommendations 
[17] in the context of epilepsy management [18] and VPA exposure [19].
Patient selection
All patients aged 0 to 14 years with at least one issue of antiepileptic drug (AED) recorded 
between 2010 and 2016 were selected. An AED was defined as a drug licensed for the 
treatment of epilepsy in France, i.e. drugs listed under the ATC code N03A, plus two 
benzodiazepines, diazepam (N05BA01) and clobazam (N05BA09). As diazepam is mainly 
authorized for febrile convulsions, patients who were prescribed diazepam only were 
excluded. Patients, who were prescribed sodium divalproex (N03AG01) or valpromide 
(N03AG02) were also excluded because these medications are mostly indicated in psychiatric 
setting. 
Data collection
For descriptive purposes different patient characteristics were collected: date of birth to 
determine the age at the beginning of the study (January 1st, 2010), gender, LTI status, CMUc 
status, which provides information on patient socio-economic level. Prescription 
characteristics were obviously studied: date of prescription, date of issue, drug issued, number 
of boxes and also information on the prescriber, as working in a healthcare facility or in the 
community. 
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Statistical analysis
For each patient matching the selection criteria and for each prescription we determined 
whether it was a prevalent or an incident use (first delivery after birth or after one year 
without AED issue). A one-year history was necessary to obtain this information and this is 
the reason why we retrospectively collected data up to 2009. We also determined which 
AEDs were prescribed (grouping them by ATC7 Code). The number of different ATC7 codes 
prescribed defined the polytherapy criterion. 
For each year, we first calculated the percentage of VPA and that of each ATC7 code other 
than VPA among incident uses, and plotted these proportions by gender and age category. We 
use the following age categories: 0-2 years, 3-6 years, 7-10 years and 11-14 years. For 
purposes of comparison, we calculated the relative reduction in prescriptions between the 
percentage of VPA prescribed in 2010-2014 and the one in 2016. We intentionally excluded 
the year 2015, during which time the EMA and ANSM promoted a huge campaign to avoid 
the use of VPA among women of childbearing age. The impact of the 2015 risk minimization 
measure was likely to be more obvious in 2016, the year we chose for comparison.
We then calculated the incidence rate of VPA prescription among prevalent uses of any other 
AEDs and plotted them by gender and age category: the number of VPA initiations was 
divided by the number of person-years (PY) with a prevalent use of another AED. The types 
of AED before VPA initiation were described. 
Finally we calculated the incidence rate for VPA discontinuations among prevalent users of 
VPA and the proportion for each ATC7 code among AED prescriptions after VPA 
discontinuation. VPA discontinuation was defined by the last VPA delivery date followed by 
at least one year without VPA issue, assuming one year of follow-up was available.
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Statistical analyses were performed using SAS 9.4 (SAS INSTITUTE, North Carolina, USA) 
via SAS Enterprise Guide®.
Regulatory approval
The study was granted regulatory approval as part of a larger program on VPA exposure 
(CNIL 03/11/2016). The study was conducted with direct access to the SNIIRAM database 
under ANSM agreement.
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2) Results
General characteristics of the study population
In the SNIIRAM database, 113,362 children fulfilled the selection criteria, 61,259 boys and 
52,103 girls. Almost all patient characteristics were similar between boys and girls (Table 1). 
The number of incident uses over the study period (seven years) was 93,557: 42,493 among 
girls and 50,064 among boys. The median age at the beginning of the study was five years. 
The most frequently prescribed antiepileptic drugs were, in decreasing order: sodium 
valproate, largely predominant, followed by diazepam, lamotrigine (LTG), levetiracetam 
(LEV), clobazam and clonazepam. Most of the drugs were prescribed in monotherapy. 
Prescribing trends for sodium valproate
Figure 1 shows the trends in VPA initiations over the study period by gender and age 
category. Focusing on children aged 0-10 years and incident uses only in 2010, the proportion 
of VPA prescriptions ranged between 40 and 50%, without a clear gap between boys (nearly 
30%) and girls (20%). Globally, the proportion remained quite stable until 2014 and then 
decreased. In 2016, the proportion of VPA still accounted for 11% of AED initiations among 
girls aged 11-14 years. 
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Figure 1. Trends in sodium valproate initiations over the study period by gender and age 
category. (2-column fitting image)
Between 2010 and 2016, the proportions of prescriptions for LEV, LTG, ethosuximide, 
gabapentin in incident use increased among girls aged 0-14 years (Figure 2).
Table 2 reports the proportion of VPA among AED initiations according to prescriber 
category. In 2010, initiation of VPA among girls by specialists (including hospital practitioner 
and neurologist or pediatrician working in community) was relatively frequent (over 40%). 
This frequency was lower in 2016 for neurologists (-24.5% between 2010 and 2016), hospital 
practitioners (-20.6%) and pediatricians (-15.6%). In contrast, the frequency of VPA use 
among AED initiations by General Practitioners (GPs) was relatively stable over the period, at 
around 20-25%.
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Figure 2. Trends in antiepileptic treatment initiations over the study period among girls aged 
0-14 years. (1-column fitting image)
Figure 3 shows trends in initiating VPA (add-on or switch) among prevalent users of any 
AED other than VPA over the study period by gender and age category. The number of PY 
treated with an AED other than VPA was around 5000 per year over the study period. In this 
population, the incidence rate for VPA prescription decreased from 18.3 in 2010 to 9.7 per 
100 PY in 2016 for girls (47% relative reduction) versus 20.3 to 16.1 per 1000 PY for boys 
(relative reduction of 21%). These relative reductions were homogeneous across the different 
age groups. 
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It can be noted that the incidence rate for VPA prescription among teenage girls (11-14 years 
of age) and young girls (7-10 years of age) was relatively low over the study period (less than 
10 for 100 PY). The most frequently prescribed AEDs just before VPA initiation were 
benzodiazepines, lamotrigine and vigabatrine, mostly in monotherapy (91% in 2010; 89% in 
2015).
Figure 3. Trends in sodium valproate initiations (add-on or switch) among children already 
treated with another antiepileptic drug over the study period, by gender and age category. (2-
column fitting image)
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Discontinuation of VPA was defined as an issue of VPA that was not followed later in the 
year by another issue of VPA, assuming one year of follow-up was available. Discontinuation 
of VPA was quite high (around 35 per 100 child-years) but quite stable over the study period 
and similar in girls and in boys. It was higher among young children (0-6 years old) than 
among older children (7-14 years old) (40 to 60 per 100 PY versus 30 per 100 PY). 
In around 70% of cases, VPA discontinuation was not followed by another AED. Before 
withdrawal of sodium valproate treatment, the antiepileptic treatment duration was for the 
majority 1 year or more (60%), while in 18% of cases it was less than 1 month (only 1 issue). 
It was different among children aged 0-2 years, for whom only 1 month of antiepileptic 
treatment before VPA withdrawal was observed in 30% of cases. 
The remaining 30% “switched” from VPA to another AED, mostly in monotherapy. 
Lamotrigine and levetiracetam were the most frequently prescribed AEDs.
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Discussion
Our study evaluating the trends in sodium valproate (VPA) prescription among children 
highlighted a number of points. 
Firstly, the proportion of VPA prescriptions among incident uses of antiepileptic drugs 
decreased in both genders over the study period, but more so among girls, especially in 
teenage girls. Over the 1993 to 2006 period, the prevalence of VPA per 1000 prescriptions 
among females (12-18 years old) significantly decreased from 0.94 (95% CI 0.80 to 1.09) to 
0.63 (95% CI 0.55 to 0.72). [7]. Over the 2000 to 2010 period, girls were prescribed sodium 
valproate significantly less often as a first-line AED (74% versus 46%). [20] Our study 
enables these observations to be updated and it points to a substantial decrease in VPA use 
among teenage girls, possibly as a result of new information released in the media on its 
teratogenic effects. [10] 
Secondly, the alternatives to VPA, for which frequencies increased during the study period, 
were mainly levetiracetam, then lamotrigine, followed by ethosuximide and gabapentin. 
Increases were always more pronounced for girls than for boys. Changes in the choice of the 
first AED for a new onset of epilepsy are similar to those observed in previous years in other 
European countries. [7,9,20] During the 2000s, it was established that the use of first-
generation AEDs (VPA, carbamazepine, phenytoin, phenobarbital) decreased over time, at 
least in developed countries, concomitantly with the arrival of new AEDs on the market. 
[5,9,21,22] More recently, a trend towards more LEV and LTG prescriptions could also be 
explained by prescribers’ knowledge of the significantly lower rates of major congenital 
malformations for these drugs. [11] 
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Thirdly, the proportion of VPA initiations among girls already under treatment greatly 
decreased for specialists but remained stable over the study period for GPs. The proportions 
of AED prescriptions by three different prescriber categories (GPs, specialists, psychiatrists) 
were studied by Hollingworth & al. in Australia over a 5-year period (2002-2007). They 
observed an increase in prescribing of new AEDs, such as levetiracetam, topiramate and 
lamotrigine, by GPs. Also, the proportion of prescriptions by GPs was the highest for 
phenytoin, followed by sodium valproate. [23] Prescriber data in this study indicated a shift 
from specialist to GP prescribing. Neurologists commonly initiate AED prescription for 
epilepsy and the subsequent prescribing is usually taken on by GPs. This pattern should be 
applied in France according to the latest recommendations. Nevertheless, VPA accounted for 
20% of AEDs initiated by a GP. In the clinical context of epilepsy, primary care should lead 
to an initiation of antiepileptic treatment to limit possible seizures and should not have to be 
delayed until the final therapeutic choice made by a specialist. Continuing prescription of 
VPA as first-line treatment by GPs could reflect difficulties in healthcare trajectories for the 
French epileptic population, with difficult access to specialized care (EEG, neurologist, 
tertiary care hospitals), compelling GPs to ensure the care of first seizures with VPA, on the 
grounds that this AED has a broad spectrum of activity. 
Finally, discontinuation of VPA was stable over the study period, among girls but also among 
boys, and did not seem to be influenced by the recommendations. In 70% of cases, the 
withdrawal of VPA was not followed by another AED, and this was all the more true among 
children aged 0-2 years. The exact reasons why treatments were discontinued is not known, 
but some situations can justify it. For instance, treatment with VPA can be discontinued after 
a diagnosis of recovery. VPA is the drug of choice for many epileptic syndromes, and widely 
prescribed by GPs. After specialist consultation or access to electroencephalogram (EEG), a 
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diagnosis other than epilepsy can be made. An antiepileptic treatment can also be prescribed 
on a temporary basis, for example in case of accidental seizure after meningitis, head trauma, 
or febrile seizures. In these cases, the treatment duration is short (a few months) and pursuit of 
antiepileptic treatment is not expected. Among older children, discontinuation of the 
antiepileptic treatment can occur in certain types of syndrome (childhood absence epilepsy, 
benign rolandic epilepsy) after a seizure-free period, or to limit the neurocognitive impact of 
AEDs. Prolonged discontinuations do not systematically lead to seizure recurrence and are 
possible for some patients. [30, 31]
Compared to previous studies, our investigation, by using a large population database over a 
recent period of time, is the first one that evaluates latest trends in prescribing valproate 
focusing on children. 
A first limitation is the definition of incident use, which could include a re-instatement of 
treatment, as it was based on a one-year AED-free period only. However, recommendations 
on VPA use encompass AED initiation as well as resumption of treatment. A second 
limitation is the fact that the SNIIRAM database does not enable the pathological context of 
prescriptions to be identified because no clinical data is available except for the hospital 
discharge diagnoses.. Nevertheless, we believe that AEDs are primarily prescribed in children 
for anticonvulsant purposes and, more importantly, our objective was to observe a decrease in 
valproate prescribing trends regardless of indication. Finally, patients in long-term facilities 
were not included in this study because AED issues for these patients were not available in 
the database. These patients often have pharmaco-resistant epilepsy, or at least epilepsy that is 
hard to stabilize with different AED prescription strategies. [23, 24]
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Conclusion
This large-scale study describes changes in paediatric prescription patterns following the 
implementation of a national information campaign on the appropriate use of VPA.
The observed trend was as expected, with a decrease in VPA initiations, especially after 2015, 
among children whether or not already treated with an AED. This decrease was observed in 
both genders, more pronounced for girls, and sharper in 2016. The proportion of VPA 
prescriptions among the different AED prescriptions decreased between 2010 and 2016 in 
favor of LTG and LEV, often used as monotherapy. Whatever the nature of the prescription 
(initiation or not), they came mainly from hospital prescribers (specialists) and from 
neurologists or pediatricians.
All prescribers reduced VPA prescriptions between 2010 and 2016, especially the 
neurologists. VPA initiation remained stable among GPs. In 2016, the Prescription and Drug 
Supply Conditions changed for VPA in France: it is now mandatory for it to be initiated by a 
specialist. Furthermore, the European Medicines Agency recently changed the 
recommendations for VPA use: it should not be prescribed to women of childbearing potential 
except if there is no other treatment option, and provided the woman is on adequate 
contraception. Further evaluations in 2016, 2017 and 2018 could be valuable.
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Table 1: Characteristics of the study population.
 Girls (N=52103) Boys (N=61259)
Age*, median (quartiles) 5 (1-9) 5 (1-9)
LTI = Epilepsy, n (%) 11541 (22,2) 13470 (22,0)
CMUC, n (%) 15719 (30,2) 19780 (32,3)
Hospitalization for epileptic seizure†, n (%) 14449 (27,7) 17497 (28,6)
Initiation of an antiepileptic treatment†, n (%) 42493 (81,6) 50064 (81,7)
Annual density of prescription of AED‡, median (quartiles) 11,9 (8,8 - 12,2) 11,7 (8,7-12,2)
Number of ATC classes experimented by child†, n (%)   
1 class    27126 (52,1) 31700 (51,7)
2 classes 14508 (27,8) 17640 (28,8)
>=3 classes 10469 (20,1) 11919 (19,5)
Taking AED treatment**, n (%)
Sodium valproate 27508 (52,8) 35873 (58,6)
Diazepam 16227 (31,1) 20529 (33,5)
Lamotrigine 8813 (16,9) 7493 (12,2)
Levetiracetam 8406 (16,1) 9043 (14,8)
Clobazam 7988 (15,3) 9229 (15,1)
Clonazepam 6824 (13,1) 8163 (13,3)
Carbamazepine 4161 (8,0) 5615 (9,2)
Topiramate 3416 (6,6) 3605 (5,9)
Ethosuximide 2711 (5,2) 2471 (4,0)
Oxcarbazepine 2603 (5,0) 3242 (5,3)
Phenytoine 209 (0,4) 261 (0,4)
Majority type of AED prescriptions†, n (%)   
>50% of prescriptions in monotherapy without VPA 25539 (49,0) 26525 (43,3)
>50% of prescriptions in monotherapy with VPA 19019 (36,5) 25743 (42,0)
>50% of prescriptions in polytherapy without VPA 2030 (3,9) 2219 (3,6)
>50% of prescriptions in polytherapy with VPA 2877 (5,5) 3611 (5,9)
No majority type of AED prescriptions 2638 (5,1) 3161 (5,2)
* Parameter calculated at the beginning of the study period, i.e. the first of January 2010.
† Parameter calculated over the study period (From 2010 until 2016).
‡ Parameter calculated over the period of prescription (from the first prescription until the last prescription identified over the study period 
before the age of 14.
** At least one supply of the AED before the age de 14 and over the study period.
LTI denotes long-term illness status which gives entitlement to full health care reimbursement, CMUC Complementary Universal Health 
Insurance status, which provides information on the patients’ socio-economic level, AED antiepileptic drug, ATC Anatomical Therapeutic 
Chemical.
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Table 2: Proportion of VPA among AED treatment initiations, by prescriber category.
Sodium valproate 2010 2011 2012 2013 2014 2015 2016*
N 4243 4330 4325 4320 4195 4081 2255
n 1807 1740 1703 1721 1552 1343 495
Hospital 
practitioner**
% 42.59 40.18 39.38 39.84 37.00 32.91 21.95
N 1901 1684 1378 1243 1223 1184 645
n 438 406 426 372 360 281 130
General 
practitioner
% 23.04 24.11 30.91 29.93 29.44 23.73 20.16
N 288 275 275 237 246 233 130
n 138 122 130 116 107 110 42
Pediatrician
% 47.92 44.36 47.27 48.95 43.50 47.21 32.31
N 428 348 338 338 339 336 172
N 177 145 131 132 116 80 29
Girls
0-14 
years
Neurologist
% 41.36 41.67 38.76 39.05 34.22 23.81 16.86
N 5250 5357 5199 5054 5071 4913 2853
n 2348 2323 2199 2145 2119 1946 1082
Hospital 
practitioner**
% 44.72 43.36 42.30 42.44 41.79 39.61 37.92
N 2083 1979 1590 1437 1401 1273 653
n 523 546 602 469 421 351 153
General 
practitioner
% 25.11 27.59 37.86 32.64 30.05 27.57 23.43
N 299 295 327 307 319 289 149
n 142 129 130 152 164 131 66
Pediatrician
% 47.49 43.73 39.76 49.51 51.41 45.33 44.30
N 401 357 311 357 310 308 167
n 177 171 159 162 146 126 58
Boys
0-14 
years
Neurologist
% 44.14 47.90 51.13 45.38 47.10 40.91 34.73
N = number of prescriptions initiated by the prescriber category
n = number of prescriptions of VPA among the previous N
*up to 31/07/2016
**physician working in a hospital, considered as a specialist
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